List view / Grid view
24 June 2016 | By Victoria White, Digital Content Producer
The method, called Patient-Based in Vivo Lethality to Optimise Treatment (PILOT), allows for the analysis of hundreds of tumour genes using only a few mice...
26 January 2016 | By Victoria White
The three-year collaboration agreement provides a framework for MD Anderson and AbbVie to efficiently choose and carry out preclinical and clinical studies evaluating new ideas in immuno-oncology...
22 December 2015 | By Victoria White
MDSCs are immune cells that “expand” when faced with cancer, inflammation or infections, giving them the unique ability to suppress the body’s T-cell response to disease...
2 December 2015 | By Victoria White
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Centre are to focus on developing new medicines for pancreatic ductal adenocarcinoma...
6 November 2015 | By Victoria White
ProCAR-NK cell therapies will be created against targets for which safety and toxicity have traditionally been limiting factors for CAR cell therapies...
30 October 2015 | By Victoria White
MD Anderson's Moon Shots Programme is an unprecedented effort and novel organisational model designed to more rapidly convert scientific discoveries into life-saving advances...
26 August 2015 | By Victoria White
Immatics US is a new company aimed at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumour types...
6 August 2015 | By Victoria White
Researchers placed cancer cells in a three-dimensional scaffold and subjected them to the forces that push, pull and continually flow through the body...
27 July 2015 | By Victoria White
Genetic aberrations have been seen as the main cause of almost all cancer but new research shows cancer can be caused solely by protein imbalances...
11 June 2015 | By Victoria White
Countering previously held beliefs, researchers have discovered that inhibiting TLR4 may not be a wise treatment strategy in all cancers...
